CN1723928A - External use medicinal composition for treating swelling paint - Google Patents

External use medicinal composition for treating swelling paint Download PDF

Info

Publication number
CN1723928A
CN1723928A CNA200510010901XA CN200510010901A CN1723928A CN 1723928 A CN1723928 A CN 1723928A CN A200510010901X A CNA200510010901X A CN A200510010901XA CN 200510010901 A CN200510010901 A CN 200510010901A CN 1723928 A CN1723928 A CN 1723928A
Authority
CN
China
Prior art keywords
radix
present
rhizoma
group
schefflerae arboricolae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA200510010901XA
Other languages
Chinese (zh)
Other versions
CN1311850C (en
Inventor
朱兆云
王京昆
赵毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan Pharmaceutical Institute
Original Assignee
Yunnan Pharmaceutical Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan Pharmaceutical Institute filed Critical Yunnan Pharmaceutical Institute
Priority to CNB200510010901XA priority Critical patent/CN1311850C/en
Publication of CN1723928A publication Critical patent/CN1723928A/en
Application granted granted Critical
Publication of CN1311850C publication Critical patent/CN1311850C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

A Chinese medicine for treating bone fracture, injury, rheumatic arthritis, periomethritis, gout, mastoplasia, etc by exterior application is prepared from 19 Chinese-medicinal materials including notoginseng, musk, liquorice root, borneol, etc. Its advantages are simple prescription and easy carrying.

Description

The externally-applied medicinal composition that treatment is swollen and ache
Technical field
The present invention relates to the pharmaceutical composition that a kind of treatment is swollen and ache, particularly relate to the externally-applied medicinal composition that a kind of treatment that with the vegetable Chinese herbal medicine is raw material is made is swollen and ache.
Background technology
Chinese patent application numbers 931112052 discloses " a kind of compound method of burn-scald medicine ", is to place ethanol to soak Radix Sanguisorbae, Cortex Phellodendri, elm endothelium and/or jujube tree endothelium, Borneolum Syntheticum and Radix Notoginseng to be mixed with the burn and scald medicinal liquid.Described medical material the ratio of each component is: Radix Sanguisorbae 70-100 part, Cortex Phellodendri 50-100 branch, elm endothelium and/or jujube tree endothelium 1-60 part, Borneolum Syntheticum 0.1-2 part, Radix Notoginseng 0.1-2 part.Chinese patent application number 02158235.1 discloses a kind of " externally-applied medicinal composition that treatment is swollen and ache ", is made by Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 72-288, Delavay ampelopsis root 72-288, Folium Craibiodendri Yunnanensis 72-288, Herba Veratri Taliensis 72-288, Radix Psammosilenes 72-288.
Summary of the invention
Purpose of the present invention is intended to provide a kind of traumatic injury, rheumatism externally-applied medicinal composition evident in efficacy, safe in utilization for the treatment of.
The externally-applied medicinal composition that treatment of the present invention is swollen and ache is the exterior-applied formulation of being made by following materials of weight proportions: Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 160-200, Radix Notoginseng 160-200, Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani) 160-200, Delavay ampelopsis root 160-200, Folium Craibiodendri Yunnanensis 160-200, Herba Veratri Taliensis 160-200, Radix Psammosilenes 160-200, Radix Aconiti Kusnezoffii 160-200, colguhoumia root 160-200, Herba Erigerontis 160-200, Radix et Rhizoma Dysosmatis 160-200, Rhizoma Paridis 160-200, Fructus Gardeniae 160-200, Pseudobulbus Bletillae (Rhizoma Bletillae) 160-200, Radix Angelicae Dahuricae 160-200, Radix Glycyrrhizae 50-70, Borneolum Syntheticum 50-70, Mentholum 50-70, Moschus 0.4-1.
The present invention is a principal agent with Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae), Radix Notoginseng, Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani), and the sweet temperature of Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) is arrogated to oneself alleviating pain and detumescence, relaxing muscles and tendons and activating QI and blood in the collateral, and expelling wind and removing dampness is used for various pain, injury and bone fracture and traumatic hemorrhage; The sweet little hardship of Radix Notoginseng, temperature is dissipating blood stasis hemostasis, the subduing swelling and relieving pain good medicine of generally acknowledging at all times, and the strong merit of setting upright is arranged; Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani) hardship, suffering, temperature, poisonous, the power of wind-damp dispelling, analgesia is quite strong; The three all has stronger blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, expelling wind and removing dampness effect and play main therapeutical effect.Radix Aconiti Kusnezoffii, Radix Psammosilenes, Delavay ampelopsis root, Folium Craibiodendri Yunnanensis, Herba Erigerontis all are the diffusing product of warm suffering, have the merit of inspiring personal yang-energy, invade in an opponent's defence between the meridians joint and the wind-cold damp pathogen gas that do not go of residence for a long time to disperse, and the effect of eliminating stasis to stop pain is arranged; Rhizoma Paridis, colguhoumia root, Radix et Rhizoma Dysosmatis, Herba Veratri Taliensis nature and flavor bitter cold, be good at heat-clearing and toxic substances removing, promoting blood circulation to remove blood stasis, reducing swelling and alleviating pain, for pyretic arthralgia (as rheumatic fever, acute stage gouty arthritis and scapulohumeral periarthritis) and the red and swollen heat pain of traumatic injury and cyclomastopathy direct removing heat from blood and promoting blood circulation, reducing swelling and alleviating pain effect are arranged, and can prevent medicine consumption impairment of QI the moon that the hot temperature of loosing is logical, be total to the assosting effect that opposes each other and yet also complement each other merit with enhancing principal agent tonneau passages through which vital energy circulates, reducing swelling and alleviating pain.Fructus Gardeniae, the Radix Angelicae Dahuricae, Pseudobulbus Bletillae (Rhizoma Bletillae) are adjuvant drug, Fructus Gardeniae, Pseudobulbus Bletillae (Rhizoma Bletillae) bitter cold, can restrain the property of warm drugs impairment of YIN dryness-transformation and receive the assistant system effect; Fructus Gardeniae also can cool the blood dissipate blood stasis on the other hand, and the phlegmatic temperament of Pseudobulbus Bletillae (Rhizoma Bletillae) can make the little apparent thickness of medicinal liquid, plays the medicine carrying effect, and the Radix Angelicae Dahuricae is antipruritic, can prevent the diseases such as pruritus that may occur after a few peoples' medication.The hot temperature of Moschus, Compendium of Material Medica are called its " logical all keys are opened meridians, saturating flesh bone ", Borneolum Syntheticum is arduous to be slightly cold, and Xin Xiang walks to scurry and is big logical product, and two medicines and Mentholum are all gone into heart channel, can go into blood by priming, promote drug transdermal to absorb, and on skin, produce refrigerant sense, to alleviate discomfort and pain; Radix Glycyrrhizae can heat-clearing and toxic substances removing, relieving spasm to stop pain, can be in harmonious proportion the cold and heat property of medicine again, relaxes the toxicity of medicine and strong, and this four flavor is messenger drug altogether.
Medicament of the present invention is a said exterior-applied formulation on the pharmaceutics.Can be the liniment made through conventional technology of raw material of the present invention and corresponding medicinal adjuvant, aerosol, liniment, rubber-emplastrum, cataplasma, gel etc.
Pharmaceutical composition of the present invention has no side effect through the external of toxicity test proof; The effect that has significant antiinflammatory, analgesia, microcirculation improvement, inhibition gouty arthritis and inhibition cyclomastopathy through pharmacodynamic study; Through clinical trial, treatment of diseases total effective rates such as traumatic injury, rheumatic arthritis, scapulohumeral periarthritis, gout and cyclomastopathy are reached more than 92%.
Pharmacodynamic study
One, antiinflammatory action research
1. to the influence of rat assist agent arthritis
Test with 70 of 150～200g rats, male and female half and half, grouping sees Table 1.Except that model control group is not done any processing, each treated animal equal every day according to dosage once in the following coating in right back ankle joint, continuous 6 days.Before the last coating, sufficient normal volume about measuring earlier behind the coating 30 minutes, in every right back sufficient plantar subcutaneous injection Freund ' s Freund's complete adjuvant 0.1ml of rat, causes after the inflammation more continuously coating 26 days.And 2h, 18h behind the Yu Zhiyan, 3d and after sufficient volume about certain hour (see Table 1 and table 2) is measured at interval, the preceding foot swelling of rat and tail, ear's erythema situation and body weight change after attention is simultaneously observed and caused scorching 8 days, and keep the score for every Mus delayed hypersensitivity by documentation standards, until causing scorching back 28 days.Put to death animal on the 28th day, cut open and get thymus, spleen and adrenal gland and weigh, calculate organ index and cause inflammation foot swelling rate all around, the significance of more every index group difference.The results are shown in Table 1, table 2, table 3 and table 4.
Experimental result shows, the present invention can suppress the primary affection of rat assist agent arthritis, offside foot swelling in the time of obviously suppressing secondary affection again and foot swelling once again, and the General Symptoms when alleviating delayed hypersensitivity do not have obvious influence to immune organ, adrenal gland's weight and body weight.
Table 1. the present invention is to the influence of rat assist agent arthritis primary affection
Group Dosage (/ only) Number of animals (only) The sufficient volume in basis (X ± SD, ml) Cause scorching back different time swelling rate (X ± SD, %)
2h 18h 3d 5d
The model contrast 10 1.25±0.09 30.01±12.23 50.59± 12.74 59.35± 25.60 45.63± 11.82
Solvent 0.1ml 10 1.26±0.11 40.54±19.97 50.67± 18.01 56.98± 22.12 53.33± 16.01
Fluocinonide 50mg 10 1.25±0.06 31.22±10.64 38.61± 6.39 * 35.48± 16.21 * 33.82± 12.22 *
YUNNAN BAIYAO DING 0.1ml 10 1.23±0.12 40.7±15.76 44.07± 18.34 56.13± 23.57 54.41± 22.88
The present invention 100% 0.1ml 10 1.34±0.13 26.77±8.19 33.55± 18.25 38.90± 15.49 33.98± 17.31
The present invention 50% 0.1ml 10 1.25±0.14 28.12±25.48 37.06± 18.63 46.91± 22.86 43.24± 22.11
The present invention 25% 0.1ml 10 1.28±0.16 32.48±14.62 44.44± 20.07 37.07± 15.39 * 40.58± 18.32
Table 2. the present invention is to the influence of rat assist agent arthritis secondary affection
Group Dosage (/ only) Number of animals (only) Cause scorching back different time swelling rate (X ± SD, 100%)
8d 12d 16d 20d 24d 28d
Cause scorching right foot Model is to clear 8 42.85± 15.25 36.71± 21.32 55.06± 23.06 56.61± 23.41 52.21± 23.60 60.08± 24.10
Solvent 0.1ml 9 50.91± 20.20 57.76± 27.25 61.92± 38.26 60.21± 34.48 55.09± 34.44 57.01± 35.54
Fluocinonide 50mg 8 22.01± 13.20 22.42± 11.94 15.23± 14.10 ** 19.23± 18.39 ** 20.13± 17.00 ** 34.35± 21.51 *
YUNNAN BAIYAO DING 0.1ml 10 49.73± 19.15 55.33± 29.22 47.28± 17.47 54.92± 30.56 63.63± 32.36 55.27± 32.80
The present invention 100% 0.1ml 9 29.49± 17.31 35.64± 21.06 38.69± 29.41 48.62± 41.81 46.08± 37.30 41.77± 37.96
The present invention 50% 0.1ml 9 39.48± 19.47 48.98± 21.13 55.42± 27.48 56.72± 23.52 50.77± 31.01 51.82± 31.99
The present invention 25% 0.1ml 8 27.07± 10.73 * 38.91± 16.28 38.10± 12.09 39.05± 13.84 40.95± 21.49 48.56± 24.39
Offside left side foot 17.37± 13.75 18.89± 14.49 20.65± 13.73 22.75± 18.43 21.65± 18.04 17.15± 11.91
11.87± 10.94 15.85± 13.74 17.82± 17.16 14.38± 16.73 18.50± 16.97 14.57± 13.61
12.37± 9.95 11.28± 7.10 4.17± 11.30 * 6.60± 10.85 * 6.42± 10.03 9.20± 7.72
20.16± 15.01 20.78± 12.44 15.56± 11.01 20.45± 14.97 22.06± 15.02 16.09± 10.57
5.35± 6.28 * 6.80± 8.32 * 14.74± 19.99 13.04± 21.00 14.24± 25.93 11.81± 23.89
16.15± 10.86 19.46± 15.02 23.65± 14.95 24.36± 17.16 20.47± 18.12 19.48± 15.28
6.96± 6.57 11.47± 10.86 11.83± 6.22 10.73± 12.36 8.82± 11.74 11.67± 10.16
Table 3. the present invention is to the influence of rat assist agent arthritis whole body pathological changes
Group Dosage (/ only) Score value Add up to (only) The U value
0 1 2 3 4
The model contrast 1 1 0 3 3 8
Solvent 0.1ml 1 1 3 2 2 9 ＞0.05
Fluocinonide 50mg 7 1 0 0 0 8 ＜0.01
YUNNAN BAIYAO DING 0.1ml 1 3 2 2 2 10 ＞0.05
The present invention 100% 0.1ml 1 6 2 0 0 9 ＜0.05
The present invention 50% 0.1ml 2 1 2 2 2 9 ＞0.05
The present invention 25% 0.1ml 1 5 2 0 0 8 ＜0.05
Table 4. the present invention is to the influence of adjuvant arthritis rats body weight, immune organ and adrenal gland's weight
Group Dosage (/kg) Number of animals (only) Body weight (X ± SD, g) Organ weight's index (X ± SD, mg/100g)
Before causing inflammation Cause scorching 15d Cause scorching 28d Thymus Spleen The adrenal gland
Model is to clear 8 181.5± 11.1 206.3± 14.1 226.3± 19.3 108.13± 45.67 467.12± 193.73 30.14± 6.15
Solvent 0.1ml 9 190.0± 12.9 217.8± 33.6 222.2± 35.1 83.76± 17.82 434.31± 91.31 32.65± 10.80
Fluocinonide 50mg 8 178.0± 12.3 153.8± 23.0 ** 175.0± 17.7 ** 26.21± 23.54 ** 451.22± 56.26 22.31± 3.74 **
YUNNAN BAIYAO DING 0.1ml 10 182.0± 14.8 191.5± 18.3 192.0± 17.4 ** 83.80± 34.71 455.07± 132.22 31.28± 8.11
The present invention 100% 0.1ml 9 192.0± 24.3 207.2± 17.9 204.4± 41.1 94.72± 43.55 420.64± 71.13 32.24± 11.07
The present invention 50% 0.1ml 9 183.5± 20.7 208.9± 16.2 215.0± 18.0 83.14± 20.60 430.13± 131.04 28.50± 5.66
The present invention 25% 0.1ml 8 191.5± 10.3 203.1± 19.4 205.5± 22.1 91.05± 31.30 490.69± 274.19 30.44± 6.94
Compare with matched group: * P＜0.05, * * P＜0.01
2. to the influence of rat Ovum Gallus domesticus album foot swelling
Get 60 of 180～235g rats, male and female half and half are pressed table 5 grouping, 10 every group.Each treated animal respectively according to dosage in the following coating in right back ankle joint once after 30 minutes, is given the whole plantar subcutaneous injection 10% fresh Ovum Gallus domesticus album normal saline solution 0.1ml of medication, and coating is once more simultaneously.Measure respectively cause scorching before and cause the sufficient volume of scorching back 0.5h, 1h, 2h, 3h, 4h and 5h, the loss of medicine on the foot sole of the foot when measuring, coating is once again after each the measurement.Causing the volumetrical rate of change of scorching metapedes with every Mus is the swelling rate.The results are shown in Table 5.
Table 5. the present invention is to the influence of rat Ovum Gallus domesticus album pedal swelling
Grouping Dosage (ml/ only) Number of animals (only) The sufficient volume in basis (X ± SD, ml) Cause scorching back swelling rate (X ± SD)
0.5h 1h 2h 3h 4h
The model contrast 0.1 10 1.33±0.18 0.46± 0.12 0.58± 0.19 0.46± 0.15 0.37± 0.14 0.27± 0.11
Solvent 0.1 10 1.38±0.25 0.44± 0.12 0.51± 0.18 0.41± 0.16 0.35± 0.18 0.24± 0.13
YUNNAN BAIYAO DING 0.1 10 1.25±0.22 0.37± 0.14 0.45± 0.12 0.31± 0.08 * 0.24± 0.11 * 0.15± 0.10 *
The present invention 100% 0.1 10 1.26±0.23 0.31± 0.13 * 0.40± 0.19 * 0.29± 0.20 * 0.18± 0.13 ** 0.13± 0.11 **
The present invention 50% 0.1 10 1.25±0.17 0.36± 0.19 0.39± 0.15 * 0.37± 0.13 0.25± 0.10 * 0.16± 0.07 *
The present invention 25% 0.1 10 1.29±0.19 0.45± 0.28 0.45± 0.31 0.35± 0.20 0.23± 0.13 * 0.15± 0.13 *
Compare with matched group: * P＜0.05, * * P＜0.01
Experimental result shows, the present invention's three dosage groups and YUNNAN BAIYAO DING group all can significantly suppress the pedal swelling of rat due to the Ovum Gallus domesticus album, and dose-effect relationship is not obvious between each group.
3. xylol causes the influence of mice auricle swelling
Get 60 of 21～24g mices, male and female half and half are pressed table 6 grouping, 10 every group.Evenly smear dimethylbenzene 0.05ml for every Mus auris dextra two sides, left ear is not painted with contrast.Each treated animal is in causing back 30 minutes of inflammation and 1h difference coating once.1h puts to death animal after the last administration, with the card punch of diameter 9mm ears is downcut with the position homalographic, and electronic analytical balance is weighed, with the difference of two auricle weight as the swelling degree.The results are shown in Table 6.
Table 6. xylol of the present invention causes the influence of mice auricle swelling
Group Dosage (ml/ only) Number of animals (only) Auricle swelling degree (X ± SD, mg) Suppression ratio (%)
Normal saline 0.05 10 15.0±3.1
Solvent 0.05 10 13.4±3.4 10.67
YUNNAN BAIYAO DING 0.05 10 9.3±3.3 ** 38.00
The present invention 100% 0.05 10 6.8±1.5 ** 54.67
The present invention 50% 0.05 10 8.3±2.4 ** 44.67
The present invention 25% 0.05 10 10.2±4.7 * 32.00
Compare with matched group: * P＜0.05, * * P＜0.01
Experimental result shows that the present invention's three dosage groups and YUNNAN BAIYAO DING group all can significantly suppress the mice caused by dimethylbenzene xylene auricle edema, and effect has dose dependent between each group.
Two, analgesic activity research
1. the Dichlorodiphenyl Acetate induced mice is turned round the influence of body pain
Get 60 of 18～20g mices, male and female half and half are pressed table 7 grouping, 10 every group.Each organizes mice respectively by 0.1ml/ dosage only in the abdominal part coating per hour once, continuous three times.Behind the last coating 30 minutes, give every Mus lumbar injection 0.6% glacial acetic acid 0.1ml/10g body weight, observe and write down the writhing response number of times in each Mus 15 minutes.The results are shown in Table 7.
Table 7. the present invention causes the influence of pain effect to mice acetic acid
Group Dosage (ml/ only) Number of animals (only) Turn round body number of times (X ± SD, inferior) Suppression ratio (%)
Normal saline 0.1 10 31.9±11.6
Solvent 0.1 10 29.0±19.2 9.09
YUNNAN BAIYAO DING 0.1 10 15.4±15.4 * 51.72
The present invention 100% 0.1 10 13.1±11.1 ** 58.93
The present invention 50% 0.1 10 20.8±13.5 * 34.80
The present invention 25% 0.1 10 32.3±15.8
Compare with matched group: * P＜0.05, * * P＜0.01
Experimental result shows that senior middle school of the present invention dosage group and YUNNAN BAIYAO DING group all can significantly suppress the writhing response that acetic acid causes the pain mice; Low dose group is compared no significant difference with the blank group.
2. mice formaldehyde is caused the influence of pain reaction
Get 60 of 19～21g mices, male and female half and half are pressed table 8 grouping, 10 every group.Each treated animal is pressed 0.05ml/ dosage only in the following coating in right back ankle joint once every day, for three days on end.Behind the last coating 30 minutes, press literature method in right back sufficient plantar subcutaneous injection 30ul 0.5% formaldehyde of mice, and the repaste medicine once single is only put into the 500ml glass beaker immediately, observes and writes down to lick in preceding 10 minutes and sting right back sufficient time and back 20 minutes and lick the time of stinging right back foot or grabbing external genitals.The results are shown in Table 8.
Table 8. the present invention causes the influence of pain reaction to mice formaldehyde
Group Dosage (ml/ only) Number of animals (only) Licked the time of stinging in preceding 10 minutes (X ± SD, second) The back was licked the time of stinging (X ± SD, second) in 20 minutes
Normal saline 0.05 10 81.0±39.5 176.9±97.6
Solvent 0.05 10 76.2±35.0 206.2±110.5
YUNNAN BAIYAO DING 0.05 10 35.6±35.0 * 124.9±74.6
The present invention 100% 0.05 10 25.6±38.5 ** 128.2±110.3
The present invention 50% 0.05 10 48.6±36.9 128.6±67.9
The present invention 25% 0.05 10 50.2±46.4 145.1±90.2
Compare with matched group: * P＜0.05, * * P＜0.01
Experimental result shows that the heavy dose of group of YUNNAN BAIYAO DING group and the present invention all causes the pain reaction to mice formaldehyde has remarkable inhibitory action, middle low dose group inhibition trend to be arranged and no difference of science of statistics.
Three, to the influence of experimental microcirculation disturbance
Select 60 of 18～21g mices for use, male and female half and half are pressed table 9 grouping, 10 every group.Laboratory temperature remains on 25 ± 1 ℃.With 10% urethane 0.15ml/10g body weight intraperitoneal injection of anesthesia animal, fixing auricle, place under the micro-circulation scanning tunnelling microscope that amplifies 240 times, (artery and vein is parallel with suitable blood capillary, be third level branch) be the object of observation, gather the preceding image of administration earlier, lumbar injection adrenalin hydrochloride 0.1mg/kg causes experimental microcirculation disturbance then.After moulding 5 minutes, each treated animal was pressed 0.01ml/ dosage auricle coating only, gathered after the moulding 5 minutes and coating after image 5,10,15 minutes the time, measure following four indexs: 1. (fluidised form is divided 5 grades: stagnation is 0 minute to the blood fluidised form; Grain stream is 1 minute; The grain linear flow is 2 minutes; Line grain stream is 3 minutes; Linear flow is 4 minutes); 2. arteriole caliber (A 3); 3. venule caliber (V 3); 4. capillary network is counted.Observe and write down the situation of change of every index.The results are shown in Table 9,10,11 and 12.
Experimental result shows, the present invention can obviously increase arteriole, venule caliber and the capillary network counting of experimental microcirculation disturbance mice due to the epinephrine.
Table 9. the present invention is to the influence (X ± SD divides) of Mice Auricle microcirculation fluidised form
Grouping Normal fluidised form After the moulding 5 minutes 5min after the administration 10min after the administration 15min after the administration
Measured value Changing value Measured value Changing value Measured value Changing value Measured value Changing value
Physiology 3.40± 3.80± 0.42± 3.90± 0.50± 3.90± 0.50± 3.88± 0.38±
Saline 0.52 0.42 0.52 0.32 0.53 0.32 0.53 0.35 0.52
Solvent 3.50± 0.53 3.80± 0.42 0.30± 0.48 3.90± 0.32 0.40± 0.52 4.00± 0.00 0.50± 0.53 4.00± 0.00 0.50± 0.53
YUNNAN BAIYAO DING 3.70± 0.48 3.90± 0.32 0.20± 0.42 4.00± 0.00 0.30± 0.48 4.00± 0.00 0.10± 0.32 4.00± 0.00 0.30± 0.48
The present invention 100% 3.60± 0.52 3.90± 0.32 0.30± 0.48 4.00± 0.00 0.40± 0.52 4.00± 0.00 0.40± 0.52 4.00± 0.00 0.33± 0.50
The present invention 50% 3.60± 0.52 3.70± 0.48 0.10± 0.32 3.80± 0.42 0.20± 0.42 3.90± 0.32 0.30± 0.48 3.90± 0.32 0.30± 0.48
The present invention 25% 3.80± 0.42 3.70± 0.67 -0.10± 0.32 3.90± 0.32 0.20± 0.42 3.90± 0.32 0.20± 0.42 3.88± 0.35 0.13± 0.35
Compare with matched group: P＞0.05
Table 10. the present invention is to the influence (X ± SD, individual) of Mice Auricle microcirculation capillary network counting
Grouping Normal counting Moulding 5 minutes 5min after the administration 10min after the administration 15min after the administration
Measured value Changing value Measured value Changing value Measured value Changing value Measured value Changing value
Normal saline 5.90± 3.28 3.70± 2.45 -2.20± 1.23 4.20± 2.44 1.70± 3.16 5.10± 4.04 -0.80± 2.90 4.88± 2.80 -0.50± 2.07
Solvent 4.10± 2.08 2.20± 1.69 1.90± 1.85 3.90± 3.07 -0.20± 2.78 4.00± 2.75 -0.10± 2.56 4.40± 2.95 0.30± 2.71
YUNNAN BAIYAO DING 5.00± 2.94 3.30± 2.95 -1.70± 1.25 4.80± 3.32 -0.20± 2.53 5.50± 3.72 0.50± 2.27 5.90± 3.28 0.90± 2.02
The present invention 100% 5.00± 2.94 3.30± 2.21 -1.70± 1.70 5.60± 2.01 0.60± 2.01 * 5.60± 1.90 0.60± 1.58 4.89± 2.32 0.11± 1.62
The present invention 50% 3.90± 1.96 1.90± 1.29 -1.90± 1.37 3.60± 1.96 -0.20± 2.10 4.20± 2.44 0.40± 1.58 3.80± 2.30 -0.10± 1.59
The present invention 25% 3.70± 2.21 2.20± 2.44 -1.50± 1.96 3.50± 2.55 -0.20± 1.87 4.10± 2.51 -0.20± 1.62 4.75± 3.06 1.38± 2.07
Compare with matched group: * P＜0.05
Table 11. the present invention is to Mice Auricle microcirculation A 3The influence of caliber (X ± SD, um)
Grouping Normal A 3Caliber Moulding 5 minutes 5min after the administration 10min after the administration 15min after the administration
Measured value Changing value Measured value Changing value Measured value Changing value Measured value Changing value
Normal saline 5.93± 0.93 4.42± 1.56 -1.51± 1.29 4.99± 1.77 -0.94± 1.34 5.72± 1.05 -0.21± 0.37 5.82± 1.23 -0.09± 0.44
Solvent 6.76± 1.27 4.68± 1.72 2.09± 1.31 4.89± 2.30 -1.88± 2.42 535± 1.57 -141± 1.69 6.09± 1.15 -0.68± 1.15
YUNNAN BAIYAO DING 6.43± 1.48 5.25± 2.28 -1.18± 1.52 6.35± 2.31 0.08± 2.12 7.59± 2.11 1.17± 1.03 ** 7.80± 2.44 1.38± 1.30
The present invention 100% 6.19± 0.97 4.68± 1.89 -1.51± 1.26 6.14± 2.25 -0.06± 1.80 7.02± 1.99 0.83± 1.72 7.34± 2.23 1.33± 2.21
The present invention 50% 5.88± 1.55 4.47± 1.52 -1.41± 1.45 5.67± 1.58 -0.16± 0.85 6.29± 1.56 0.41± 1.01 * 6.60± 1.92 0.73± 1.42
The present invention 25% 6.92± 1.30 5.15± 1.66 -1.76± 0.79 6.16± 2.05 -0.68± 1.70 6.50± 1.89 -0.42± 1.44 7.28± 1.28 0.20± 0.78
Compare with matched group: * P＜0.05, * * P＜0.01
Table 12. the present invention is to Mice Auricle microcirculation V 3The influence of caliber (X ± SD, um)
Grouping Normal V 3Caliber Moulding 5 minutes 5min after the administration 10min after the administration 15min after the administration
Measured value Changing value Measured value Changing value Measured value Changing value Measured value Changing value
Normal saline 6.97± 1.30 5.67± 1.06 -1.30± 0.89 5.93± 1.61 -1.04± 1.28 6.29± 1.65 0.68± 1.13 6.05± 1.76 -0.72± 1.15
Solvent 7.13± 1.72 6.50± 1.58 -0.63± 0.73 7.33± 2.33 0.21± 1.40 7.44± 2.37 0.31± 1.16 7.07± 2.42 0.05± 1.19
YUNNAN BAIYAO DING 7.13± 1.30 5.95± 1.27 -1.18± 0.88 7.44± 1.49 0.31± 1.43 8.01± 1.65 0.88± 1.16 * 8.37± 1.46 1.25± 1.43
The present invention 100% 6.77± 0.84 6.35± 0.94 0.42± 1.00 7.49± 1.01 0.72± 0.92 ** 8.32± 1.49 1.56± 1.12 ** 7.96± 1.71 1.30± 1.46 *
The present invention 50% 7.18± 1.68 6.34± 1.68 -0.84± 1.30 6.97± 1.33 -0.21± 0.82 7.39± 1.14 0.21± 1.41 7.80± 1.15 0.62± 1.03 *
The present invention 25% 6.82± 1.21 6.09± 1.57 -0.42± 1.80 7.28± 1.94 0.31± 1.84 7.33± 1.54 0.57± 1.03 7.74± 1.96 0.78± 1.76
Compare with matched group: * P＜0.05, * * P＜0.01
Four, the arthritic effect of gout
1. to the bullate influence of uric acid sodium inducing mouse foot
Test is divided into 5 groups, 10 every group at random with 50 male mices.Every day coating medicine-feeding once, successive administration 3 days, positive drug is an XUESHANJINLUOHAN ZHIOTNG TUMOJI.After the last administration 30 minutes, at the right back sufficient pad subcutaneous injection uric acid sodium normal saline suspension 0.05ml of portion; Induce the generation of gouty arthritis.Respectively cause scorching before and cause scorching back 1,2,4,6 hour, cause 0.5cm place diameter under the scorching limb ankle joint with projector (amplifying 6.5 times) survey; So that the difference before and after scorching is made the arthritic swelling degree of gouty.Average and the matched group of getting each administration group compare, and carry out statistical test.The result shows that stock solution of the present invention is to the antiinflammatory action highly significant of mice gouty arthritis.
2. uric acid sodium is induced the bullate influence of rat foot
Test is divided into 5 groups, 10 every group at random with 50 male mices.Every day coating medicine-feeding once, successive administration 3 days, positive drug is an XUESHANJINLUOHAN ZHIOTNG TUMOJI.After the last administration 30 minutes, at the right back sufficient pad subcutaneous injection uric acid sodium normal saline suspension 0.05ml of portion; Induce the generation of gouty arthritis.Respectively cause scorching before and cause scorching back 1,2,4,6 hour, cause 0.5cm place diameter under the scorching limb ankle joint with projector (amplifying 6.5 times) survey; So that the difference before and after scorching is made the arthritic swelling degree of gouty.Average and the matched group of getting each administration group compare, and carry out statistical test.The result shows that stock solution of the present invention is to the antiinflammatory action highly significant of rat gouty arthritis.
Five. to the influence of cyclomastopathy
1. to the influence of diethylstilbestrol induced mice cyclomastopathy
Advance 60 female mices, be divided into 6 groups at random, 10 every group.Except that the normal control group, all the other respectively organize the equal lumbar injection diethylstilbestrol of mice (15mg/kg), and 1 day 1 time at interval, continuous 10 times.Each administration group is coated with outside respectively and gives various dose of the present invention in moulding; RUZENGNING JIAONANG, normal control group and model control group, every day 1 time, successive administration 20 days.After last 1 administration 1 hour, the pentobarbital sodium anesthetized animal was measured the diameter of respectively organizing mice axil fore udder with precision vernier callipers; Get mammary gland tissue and do section, and keep the score by mammoplasia's pathological changes criterion, the result as seen, the mice cyclomastopathy that each dosage group of the present invention can significantly suppress diethylstilbestrol and caused alleviates lesion degree.
2. to the outgrowth influence of rat mammary gland due to the diethylstilbestrol
Advance 55 female rats, be divided into 6 groups at random, 10 every group.Except that the normal control group, all the other respectively organize the equal lumbar injection diethylstilbestrol of rat (20mg/kg), and 1 day 1 time at interval, continuous 10 times.Each administration group is coated with outside respectively and gives various dose of the present invention in moulding; RUZENGNING JIAONANG, normal control group and model control group, every day 1 time, successive administration 20 days.After last 1 administration 1 hour, the pentobarbital sodium anesthetized animal was measured the diameter of respectively organizing rat axil fore udder with precision vernier callipers; Get mammary gland tissue and do section, and keep the score by mammoplasia's pathological changes criterion, the result as seen, the rat mammary gland hypertrophy that each dosage group of the present invention can significantly suppress diethylstilbestrol and caused alleviates the breast lesion degree.
The specific embodiment
Embodiment 1:
Getting 0.8 part of 60 parts of Borneolum Syntheticum, 60 parts of Mentholums, Moschus adds ethanol and makes it dissolving in right amount, 180 parts of all the other Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae)s, 180 parts of Delavay ampelopsis root, 180 parts of Folium Craibiodendri Yunnanensiss, 180 parts of Herba Veratri Taliensis, 180 parts of Radix Psammosileness, 180 parts of Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani)s, 180 parts of Radix Aconiti Kusnezoffii, 180 parts of colguhoumia roots, 180 parts of Herba Erigerontiss, 180 parts of Radix Notoginseng, 180 parts of Radix et Rhizoma Dysosmatiss, 180 parts of Rhizoma Paridis, 180 parts of Fructus Gardeniae, 180 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 180 parts of the Radixs Angelicae Dahuricae, Radix Glycyrrhizae are ground into coarse powder for 60 parts, mixing, soak into finite concentration ethanol, percolation, the collection liquid of filtering, cold preservation is filtered, and is standby.Getting it filled adds standby medicinal liquid with film resin, stir, and the room temperature swelling, heating in water bath makes dissolving, and it is an amount of to add alcoholic solution such as Mentholum and glycerol, stirs, and packing promptly gets gel.
Embodiment 2:
Borneolum Syntheticum 60, Mentholum 60, Moschus 0.8 add ethanol makes it dissolving, all the other Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae)s 180, Delavay ampelopsis root 180 in right amount, Folium Craibiodendri Yunnanensis 180, Herba Veratri Taliensis 180, Radix Psammosilenes 180, Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani) 180, Radix Aconiti Kusnezoffii 180, colguhoumia root 180, Herba Erigerontis 180, Radix Notoginseng 180, Radix et Rhizoma Dysosmatis 180, Rhizoma Paridis 180, Fructus Gardeniae 180, Pseudobulbus Bletillae (Rhizoma Bletillae) 180, the Radix Angelicae Dahuricae 180, Radix Glycyrrhizae 60 is ground into coarse powder, mix, soak into finite concentration ethanol, percolation is collected the liquid of filtering, add solution such as above-mentioned Borneolum Syntheticum, cold preservation is filtered, and packing promptly gets liniment.
Embodiment 3:
Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 180, Delavay ampelopsis root 180, Folium Craibiodendri Yunnanensis 180, Herba Veratri Taliensis 180, Radix Psammosilenes 180, Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani) 180, Radix Aconiti Kusnezoffii 180, colguhoumia root 180, Herba Erigerontis 180, Radix Notoginseng 180, Radix et Rhizoma Dysosmatis 180, Rhizoma Paridis 180, Fructus Gardeniae 180, Pseudobulbus Bletillae (Rhizoma Bletillae) 180, the Radix Angelicae Dahuricae 180, Radix Glycyrrhizae 60 is ground into coarse powder, and mixing soaks into percolation with finite concentration ethanol, the collection liquid of filtering filters, and gets Borneolum Syntheticum 60, Mentholum 60, Moschus 0.8 is dissolved in filtrate, and cold preservation is filtered, and behind adding Tween-80, propylene glycol and the medicinal liquid mixing, leaves standstill.Medicinal liquid is poured in the clean container, be pressed into third butane gas, promptly get aerosol with pressing machine.

Claims (2)

1, the externally-applied medicinal composition that swells and ache of a kind of treatment is characterized in that the exterior-applied formulation of being made by following materials of weight proportions: Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 160-200, Radix Notoginseng 160-200, Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani) 160-200, Delavay ampelopsis root 160-200, Folium Craibiodendri Yunnanensis 160-200, Herba Veratri Taliensis 160-200, Radix Psammosilenes 160-200, Radix Aconiti Kusnezoffii 160-200, colguhoumia root 160-200, Herba Erigerontis 160-200, Radix et Rhizoma Dysosmatis 160-200, Rhizoma Paridis 160-200, Fructus Gardeniae 160-200, Pseudobulbus Bletillae (Rhizoma Bletillae) 160-200, Radix Angelicae Dahuricae 160-200, Radix Glycyrrhizae 50-70, Borneolum Syntheticum 50-70, Mentholum 50-70, Moschus 0.4-1.
2, the externally-applied medicinal composition that swells and ache according to the described treatment of claim 1 is characterized in that the exterior-applied formulation of being made by following materials of weight proportions: Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 180, Radix Notoginseng 180, Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani) 180, Delavay ampelopsis root 180, Folium Craibiodendri Yunnanensis 180, Herba Veratri Taliensis 180, Radix Psammosilenes 180, Radix Aconiti Kusnezoffii 180, colguhoumia root 180, Herba Erigerontis 180, Radix et Rhizoma Dysosmatis 180, Rhizoma Paridis 180, Fructus Gardeniae 180, Pseudobulbus Bletillae (Rhizoma Bletillae) 180, the Radix Angelicae Dahuricae 180, Radix Glycyrrhizae 60, Borneolum Syntheticum 60, Mentholum 60, Moschus 0.8.
CNB200510010901XA 2005-07-07 2005-07-07 External use medicinal composition for treating swelling paint Active CN1311850C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB200510010901XA CN1311850C (en) 2005-07-07 2005-07-07 External use medicinal composition for treating swelling paint

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB200510010901XA CN1311850C (en) 2005-07-07 2005-07-07 External use medicinal composition for treating swelling paint

Publications (2)

Publication Number Publication Date
CN1723928A true CN1723928A (en) 2006-01-25
CN1311850C CN1311850C (en) 2007-04-25

Family

ID=35923642

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200510010901XA Active CN1311850C (en) 2005-07-07 2005-07-07 External use medicinal composition for treating swelling paint

Country Status (1)

Country Link
CN (1) CN1311850C (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101347477B (en) * 2008-06-16 2010-12-01 云南省药物研究所 Medicament composition for treating rheumatoid arthritis
WO2011089161A1 (en) * 2010-01-19 2011-07-28 Medizinische Universität Wien Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
CN101632756B (en) * 2008-07-24 2011-08-24 张国政 Traditional Chinese medicine for treating malignant tumours and preparation method thereof
CN102406840A (en) * 2011-11-18 2012-04-11 云南省药物研究所 Gel binder for treating swelling and pain and its preparation method
CN102743554A (en) * 2012-06-07 2012-10-24 王晓兵 Externally applied plaster treating rheumatic arthralgia
CN104288450A (en) * 2014-09-30 2015-01-21 江苏奇力康皮肤药业有限公司 Method for preparing pain killer liniment containing short-pedicel aconite root
CN104721480A (en) * 2015-03-13 2015-06-24 三峡大学 External Chinese herbal medicine composition for treating traumatic injury and preparation method and application thereof
CN111544525A (en) * 2020-06-09 2020-08-18 周勇 Traditional Chinese medicine external preparation for treating bone diseases
CN113491744A (en) * 2021-08-26 2021-10-12 付宝麟 Traditional Chinese medicine external ointment paste and preparation method and application thereof
CN114634537A (en) * 2022-04-12 2022-06-17 云南省药物研究所 Preparation method and application of diterpene in gold leaves

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102293955B (en) * 2011-09-19 2013-04-17 中科博方（厦门）生物科技有限公司 Chinese medicinal composition for treating gout, and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1260993A (en) * 1999-11-30 2000-07-26 朱敬荣 Exterior-applied medicine for treating soft tissue pain
CN100531789C (en) * 2003-03-12 2009-08-26 湘潭钢铁集团有限公司 Chinese medicine for treating injury

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101347477B (en) * 2008-06-16 2010-12-01 云南省药物研究所 Medicament composition for treating rheumatoid arthritis
CN101632756B (en) * 2008-07-24 2011-08-24 张国政 Traditional Chinese medicine for treating malignant tumours and preparation method thereof
WO2011089161A1 (en) * 2010-01-19 2011-07-28 Medizinische Universität Wien Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
CN102406840B (en) * 2011-11-18 2015-01-21 云南省药物研究所 Gel binder for treating swelling and pain and its preparation method
CN102406840A (en) * 2011-11-18 2012-04-11 云南省药物研究所 Gel binder for treating swelling and pain and its preparation method
CN102743554A (en) * 2012-06-07 2012-10-24 王晓兵 Externally applied plaster treating rheumatic arthralgia
CN102743554B (en) * 2012-06-07 2015-04-22 王晓兵 Externally applied plaster treating rheumatic arthralgia
CN104288450A (en) * 2014-09-30 2015-01-21 江苏奇力康皮肤药业有限公司 Method for preparing pain killer liniment containing short-pedicel aconite root
CN104721480A (en) * 2015-03-13 2015-06-24 三峡大学 External Chinese herbal medicine composition for treating traumatic injury and preparation method and application thereof
CN104721480B (en) * 2015-03-13 2017-12-12 三峡大学 Treat Chinese herbal medicine for external use composition of traumatic injury and its preparation method and application
CN111544525A (en) * 2020-06-09 2020-08-18 周勇 Traditional Chinese medicine external preparation for treating bone diseases
CN113491744A (en) * 2021-08-26 2021-10-12 付宝麟 Traditional Chinese medicine external ointment paste and preparation method and application thereof
CN114634537A (en) * 2022-04-12 2022-06-17 云南省药物研究所 Preparation method and application of diterpene in gold leaves

Also Published As

Publication number Publication date
CN1311850C (en) 2007-04-25

Similar Documents

Publication Publication Date Title
CN1311850C (en) External use medicinal composition for treating swelling paint
CN103169928B (en) Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof
CN1836720A (en) Chinese medicine composition for treating arthritis or gout and preparing method thereof
CN104474076A (en) Traditional Chinese medicine composition for treating eczema
CN103263488B (en) Chinese medicine fumigation-washing decoction for treating capecitabine extremities syndrome
CN102058673B (en) Chinese medicine composition for expelling wind and removing dampness and preparation method thereof
CN102247581B (en) Medicament for treating myoma of uterus
CN110742993A (en) Pain-relieving and swelling-diminishing plaster and preparation method and application thereof
CN100355450C (en) Qinchuan Tongbi tablet
CN103386022A (en) Chinese medicine composition for treating tuberculous pleurisy
CN102698014B (en) Chinese medicinal composition for treating bone-related diseases and preparation method and application thereof
CN112915173A (en) Traditional Chinese medicine composition for treating orthopedic diseases, preparation method and application
CN101829291B (en) Traditional Chinese medicine preparation for treating rheumatism and preparation method thereof
CN102670977A (en) Chinese medicinal composition for treating arthralgia, preparation method and applications of Chinese medicinal composition
CN1695682A (en) External use preparation for treating rheumatisma and bone injuries
CN1899471A (en) External use muscle relaxing preparation for treating traumatic injury and rheumatism stagnation pain and its preparing method
CN1724055A (en) Medicinal composition for treating traumatic surface
CN103272028B (en) A kind of medicine for the treatment of traumatic injury and rheumatic arthralgia
CN105079206A (en) Pain relieving traditional Chinese medicine composition and preparation method thereof
CN101214328A (en) Medicament for treating rheumatism wind-dampness pain and preparation thereof
CN116832132B (en) Chinese medicinal composition and preparation for relieving pain and numbness, and preparation method and application thereof
CN114748594B (en) Mongolian medicine for treating rheumatic arthritis
CN110420305B (en) Traditional Chinese medicine composition for treating chronic muscle injuries and preparation method thereof
CN109806321B (en) A Chinese medicinal composition, its preparation method and application in preparing medicine for treating trauma
CN1279967C (en) Medicine of regional external application for treating petvic inflammatory disease of women and preparing method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20060125

Assignee: Yunnan Baiyao Group Corp., Ltd.

Assignor: Yunnan Pharmaceutical Institute

Contract record no.: 2014530000099

Denomination of invention: External-use medicinal composition for treating gall

Granted publication date: 20070425

License type: Common License

Record date: 20140909

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model